M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents.
Ridhima Goel,Davide Cao,Davide Cao,Rishi Chandiramani,Anastasios Roumeliotis,Moritz Blum,Deepak L. Bhatt,Dominick J. Angiolillo,Junbo Ge,Ashok Seth,Shigeru Saito,Mitchell W. Krucoff,Ken Kozuma,Rajendra M Makkar,Sripal Bangalore,Lijuan Wang,Kai Koo,Franz-Josef Neumann,James B. Hermiller,Giulio G. Stefanini,Marco Valgimigli,Roxana Mehran +21 more
TL;DR: To investigate the impact of ischemic and bleeding risk factors on long‐term clinical outcomes of patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) with everolimus‐eluting stents, a large number of patients are diagnosed with DM.
Journal ArticleDOI
Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.
Marco Valgimigli,Gianluca Campo,Gianfranco Percoco,Luca Pellegrino,Gabriele Guardigli,Roberto Ferrari +5 more
TL;DR: Tirofiban, administered in the upstream setting - based on an infusion of a 30-min bolus - reduced the incidence of major adverse cardiovascular events in patients with non-ST segment elevation acute coronary syndromes, compared with heparin alone.
Journal ArticleDOI
[ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome].
Leonardo De Luca,Leonardo Bolognese,Marco Valgimigli,Roberto Ceravolo,Gian Battista Danzi,P.P. Piccaluga,Serena Rakar,Alberto Cremonesi,Francesco Bovenzi +8 more
TL;DR: In this paper, a review of the use of platelet ADP P2Y12 receptor antagonists (i.e., prasugrel and ticagrelor) for in-hospital treatment of acute coronary syndrome (ACS) patients is presented.
Journal ArticleDOI
Shifting the focus to recurrences: so good we can afford it or too bad we cannot avoid it?
TL;DR: The threat of early (i.e., within the first 30 days) stent thrombosis (ST) has accompanied percutaneous coronary intervention since the early days of stent intervention.
Journal Article
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial
Pierluigi Tricoci,Edmond Chen,Megan L. Neely,Amelia Wall Warner,Peggy H. Wong,Peter Sinnaeve,Lars Wallentin,Lisa K. Jennings,Robert F. Storey,PE Aylward,Harvey D. White,Frans Van de Werf,Paul W. Armstrong,Claes Held,Marco Valgimigli,Robert A. Harrington,John Strony,Kenneth W. Mahaffey,David J. Moliterno +18 more
TL;DR: CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial.